Navigation Links
Savient Announces the Election of Robert G. Savage to its Board of Directors
Date:12/5/2012

BRIDGEWATER, N.J., Dec. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Robert (Bob) G. Savage has been elected to the Company's Board of Directors, effective December 5, 2012.

"Bob is a proven leader with an exceptional track record of success, and we are fortunate to have a pharmaceutical executive with such a wealth of experience join our Board of Directors," stated Stephen O. Jaeger, Chairman of Savient's Board of Directors.

Mr. Savage is currently President and CEO of Strategic Imagery LLC, a consulting company of which he is the principal.  Previously, Mr. Savage was Group Vice President and President of the Worldwide General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003.  Prior to that role, he held several senior positions with Johnson & Johnson, including Worldwide Chairman of the Pharmaceuticals Group, Company Group Chairman for the North American pharmaceuticals business, President of Ortho-McNeil Pharmaceuticals and Vice President of Sales and Marketing. Earlier in his career, he served in a variety of senior marketing, operations, business development and strategic planning positions for Hoffmann-La Roche, Inc.  Mr. Savage currently serves as a director of EpiCept Corporation, Nuovo Biologics and The Medicines Company.  Mr. Savage received a B.S. in Biology from Upsala College and an M.B.A. from Rutgers University.

"Given Bob's extensive experience in domestic and international marketing, business development and operations, we are confident that he will immediately prove to be an invaluable addition to the board and as an advisor to our senior management team especially in light of the anticipated approval and launch of KRYSTEXXA® in the EU," said Lou Ferrari, President and Chief Executive Officer of Savient.  "His strategic vision and expertise in orchestrating major product launches with renowned success will be instrumental to Savient's ongoing commitment to providing KRYSTEXXA as a treatment option to patients suffering from refractory chronic gout (RCG) in the U.S. and around the world." 

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com

SVNT - GContact:Savient Pharmaceuticals, Inc.

Burns McClellan John P. Hamill

Caitlyn MurphySenior Vice President and Chief Financial Officercmurphy@burnsmc.com information@savient.com

(212) 213-0006(732) 418-9300
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
2. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
3. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
4. Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Savient Pharmaceuticals Adopts Stockholder Rights Plan
6. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
7. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
8. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
9. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Harrington Discovery Institute at University Hospitals Case Medical Center Announces Grant Funding to Physician-Scientists at Major Academic Medical Centers to Support New Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... BOSTON , March 28, 2017 /PRNewswire/ ... today announced a partnership with premium news ... allows pharmaceutical companies to extract key insights from ... text mining technology. The Linguamatics I2E ... top 20 global pharmaceutical companies. The Linguamatics-Dow Jones ...
(Date:3/28/2017)... Md. , March 28, 2017  CASI ... to innovative therapeutics addressing cancer and other unmet ... the American Association for Cancer Research annual meeting.  ... 3 is entitled "Evaluation of ENMD-2076 in ... and the second poster to be presented on ...
(Date:3/28/2017)... , March 28, 2017 ... research with Cambridge ... Consortium   The Milner Therapeutics Institute today announces ... Elysium Health has committed significant investment for collaborative projects with ... next four years. This is the first major research investment ...
Breaking Medicine Technology:
(Date:3/28/2017)... Vilnius, Lithuania (PRWEB) , ... March 28, 2017 ... ... identification technologies, today announced the release of two biometric time and attendance tracking ... Bio Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition ...
(Date:3/28/2017)... Ohio (PRWEB) , ... March 28, 2017 , ... Columbus ... was selected as one of few medical professionals in the country to sit on ... Founder of Juvly Aesthetics, in just 2 years Dr. Harper helped propel the clinic ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Camp Conference in Atlantic City March 13-16, was a busy spot this year. ... professional staff discussed strategies for preventing outbreaks among camp communities during the upcoming ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... their profession as their value increases in the healthcare workforce, according to a ... as job boards, career fairs, and candidate leads to healthcare employers of physicians ...
(Date:3/27/2017)... WI (PRWEB) , ... March 27, 2017 , ... ... new patients for custom smile makeovers without requiring a referral. Trimble ... orthodontics, gum disease treatment, cosmetic dentistry and dental implants. Whether patients have discolored, ...
Breaking Medicine News(10 mins):